Targeted News Service

Inlexzo Assigned Permanent Billing Code, Supporting Access for Patients With Certain Bladder Cancers
April 02, 2026

RARITAN, New Jersey, April 2 -- Johnson and Johnson Innovative Medicine issued the following news release on April 1, 2026:

* * *

INLEXZO(TM) (gemcitabine intravesical system) Assigned Permanent Billing Code, Supporting Access for Patients with Certain Bladder Cancers

- INLEXZO permanent J-code (J9183) effective April 1

*

Johnson & Johnson (NYSE:JNJ) today announced the permanent Healthcare Common Procedure Coding System (HCPCS . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form